The Market for Synthetic Biology Products and Technologies Shows Potential for Becoming One of the Quickest Growing Areas in the Life Science Industry

Business Wire, Jan 24, 2006

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c31390) has announced the addition of Synthetic Biology, A New Paradigm For Biological Discovery to their offering.

Synthetic biology's impact on the healthcare industry is examined in a newly released report, "Synthetic Biology, A New Paradigm for Biological Discovery", which reveals the market for synthetic biology products and technologies as potentially one of the fastest growing segments of the life sciences market. Although the research market is currently $600M, the potential for growth in the next 10 years is projected to expand this market to over $3.5B. The report is based on in-depth interviews of leading scientific researchers and biotechnology executives and presents the current research and how it may be directly applied to the development of tools and systems for clinical, pharmacological and environmental applications. It also shows that new drug applications discovered through synthetic biology have streamlined the pharmaceutical industry's ability to deliver new therapeutic agents.

ABOUT SYNTHETIC BIOLOGY

What began with DNA cloning is becoming one of the most essential areas of biological research today: synthetic biology. The field of synthetic biology comprises experts from different fields of study, such as biochemists, molecular biologists, engineers and organic chemists, who take existing biological pieces, transform them into micro-machines and create artificial systems that mimic the properties of living systems. By creating systems that mimic what nature has created, scientists can discover the basic principles that rule living systems, manipulate these systems, and eventually find treatments for many diseases plaguing humanity. Today's synthetic biologists are looking to channel genetic engineering from a hit-or-miss field of discovery to the type of discipline used by engineers to build bridges, computers and buildings. This approach can translate into more specific anticancer therapies and anti-viral drugs, as well as more efficient drug delivery systems that will have a significant impact on the healthcare industry.

Topics Covered
1 Introduction.
2 Oligonucleotides/DNA
3 RNA
4 Peptides-based Molecules
5 Metabolites
6 Organisms
7 Environmental Research
8 Synthetic Biology Informatics
9 Potential Hazards of Synthetic Biology
10 Synthetic Biology Market Overview
11 Selected Synthetic Biology Thought-leader Profiles
12 Expert Interviews
13 Synthetic Biology Companies
List of Figures
List of Tables

Summary

This report defines the overall field of synthetic biology and provides a definition of synthetic biology based on the interpretations of engineers, chemists and biologists who specialize in this field. Although there are several variations on the definition of synthetic biology, there are commonalities which hold throughout and are discussed. Ongoing research from academic institutions as well as biotechnology and pharmaceutical companies are discussed at length. Discoveries and applications from the field of synthetic biology, both current and future, are detailed, and business opportunities from these applications are investigated. Biotechnology and pharmaceutical companies as well as academicians involved in synthetic biological research are mentioned, along with partnerships formed between the different industries. As much of the research begins in the laboratories of the academic institutions and then branches out to the companies that can advance and market it, this report begins with a discussion of the definition of synthetic biology.

Companies Mentioned

- Affibody - Affymax Inc. - Alnylam Pharmaceuticals - Amyris Biotechnologies - Biotica Technology Ltd. - Cambrios Technologies Corp. - Cellicon Biotechnologies, Inc. - Codon Devices - Diversa Corporation - Genospectra - Human Genome Sciences - Idera Pharmaceuticals, Inc. - Infinity Pharmaceuticals - Maxygen - Synthetic Genomics - Vector Objects - Vion Pharmaceuticals, Inc. - Amyris Biotechnologies - Institute for OneWorld Health - CGI Pharmaceuticals - Serono SA - Schering AG - Pfizer - Affymetrix

Lilly - Diversa - DuPont - Merck - BASF - Bayer Animal Health - DSM Pharma Chemicals - Givaudan Flavors Corporation - GlaxoSmithKline - Invitrogen Corporation - Medarex - XOMA - Diversa - Eragen - Bayer HealthCare - Luminex Corporation - Blood Center of SE Wisconsin - Genome Therapeutics Corporation - Luminex - Emory University - Promega - Aventis - Gilead - Archemix - Nuvelo - Country of Samoa - Xantos Biomedicine AG - NascaCell IP - PSF Biotech AG

For more information visit http://www.researchandmarkets.com/reports/c31390